SEC Form 4 · accession 0001209191-15-079159
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart A Arbuckle
Officer — EVP\Chief Commercial Officer
Period of report
Nov 5, 2015
Accepted (ET)
Nov 9, 2015 · 5:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 5, 2015 | M | 5,664 | $45.11 | A | 110,412 | D | |
| Common Stock | Nov 5, 2015 | M | 600 | $77.31 | A | 111,012 | D | |
| Common StockF2,F3 | Nov 5, 2015 | S | 2,444 | $122.46 | D | 108,568 | D | |
| Common StockF2,F4 | Nov 5, 2015 | S | 2,400 | $123.04 | D | 106,168 | D | |
| Common StockF2,F5 | Nov 5, 2015 | S | 1,220 | $124.59 | D | 104,948 | D | |
| Common StockF2,F6 | Nov 5, 2015 | S | 200 | $125.17 | D | 104,748 | D | |
| Common Stock | holding | — | — | — | 140 | I | 401(k) |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F7 | $45.11 | Nov 5, 2015 | M | 5,664 | D | — | Feb 4, 2023 | Common Stock | 5,664 | 28,320 | D |
| Stock Option (right to buy)F8 | $77.31 | Nov 5, 2015 | M | 600 | D | — | Feb 4, 2024 | Common Stock | 600 | 41,900 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
- F2Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $122.46 (range $121.84 to $122.82).
- F4Open market sales reported on this line occurred at a weighted average price of $123.04 (range $122.84 to $123.60).
- F5Open market sales reported on this line occurred at a weighted average price of $124.59 (range $124.08 to $124.99).
- F6Open market sales reported on this line occurred at a weighted average price of $125.17 (range $125.13 to $125.21).
- F7The option vests in 16 quarterly installments from 02/05/2013.
- F8The option vests in 16 quarterly installments from 02/05/2014.